Westpac Profit Dips 3% as CEO Departs, Eyes Interest Rate Cuts to Boost Lending 
Shiba Inu Golden Cross Stumbles as SHIB Dives: Can This Technical Event Rescue Its Price? 
Huawei Powers Up China’s Digital Yuan Integration with HarmonyOS NEXT, Reaching 1 Billion Users 
'I'm Completely Fed Up': Shiba Inu's Shytoshi Kusama Issues Urgent Alert to SHIB Fans 
Crypto Markets Could Swing Wildly if US Election Results Remain Unclear, Analysts Say 
Westpac's Profit Declines Amid Rising Costs, But Dividend Boosts Investor Confidence 
Chinese Solar Firms Shift Production to Avoid U.S. Tariffs, Expanding in Southeast Asia 
Michigan Pension Fund Leads in Ethereum ETF Holdings With New $11M Investment 
Nvidia and Elon Musk's xAI Reportedly Eye Landmark Investment Deal 
Tesla's First Philippine Store Opens Nov. 9, Bringing EV Sales to Manila's Uptown Bonifacio 
Australia Shifts Focus from Lockheed Martin Satellite Project to Multi-Orbit Space Strategy 
SK hynix Debuts Industry-Leading 48GB 16-High HBM3E Memory, Revolutionizing AI Accelerator Performance 
Tesla Defies Musk's No-Endorsement Rule by Signing Korean Olympian Kim Ye-ji 
Suzuki Debuts First Electric SUV Bound for Toyota with New Branding and Cutting-Edge Design 
Nvidia, Facebook Urge Supreme Court to Dismiss Investor Fraud Lawsuits 
XRP Surges on Bullish RSI Divergence; Testing Critical Resistance Levels 
Tesla Closes $499 Million Solar Loan Debt Sale, Boosting Asset-Backed Securities Market 
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
